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Abstract
Aim of the study: Patients with metabolic syndrome (MetS) have an increased risk of cardiovascular disease. Data
obtained from muscle biopsies have demonstrated altered insulin signaling (IS) in patients with MetS. The IS
regulates critical cell functions including molecular-regulated cellular metabolite fluxes, protein and energetic
metabolism, cell proliferation and apoptosis with consequent regulation of cell life including endothelial
homeostasis and blood coagulation. However, little is known about blood cell IS in MetS patients. The aim of this
study was to develop a method to evaluate IS in peripheral lymphocytes to identify altered intracellular molecules
in patients with MetS to use as risk biomarkers of vascular thrombosis.
Patients and Methods: We investigated 40 patients with MetS and 20 controls. MetS was defined according to
guidelines from the US National Cholesterol Education Program Adult Treatment Panel III. Blood samples were
taken from all participants. Total mononuclear cells were isolated from peripheral blood using density gradient
centrifugation. IS molecules were evaluated using Western blot analysis followed by computer-assisted
densitometer evaluation.
Results: Lymphocytes of MetS patients showed a reduced mTOR expression (the mammalian target of rapamycin)
which is a fundamental molecule of IS. Major impairment of IS was confirmed by reduced upstream and
downstream mTOR molecules which regulate fundamental cells metabolic functions.
Conclusions: In patients with MetS, we found a reduction of mTOR and other mTOR-related molecules involved in
insulin resistance, cell repair, coagulation and vasculogenesis. A reduced expression of mTOR may reflect an
increased risk of vascular thrombosis.
Background
Metabolic syndrome (MetS) is a cluster of various clini-
cal cardiovascular risk factors including obesity, dyslipi-
demia and hypertension, and is characterized by high
fasting circulating insulin levels [1,2].
At present however, there are at least six operating
definitions of MetS. Despite certain common features,
these definitions differ for their relevant specific criteria
[3]. Recently, concern has been raised for MetS, and no
unifying cause of the syndrome has yet been identified
[4]. Furthermore, the precise pathophysiological
characteristics underlying the association of different
cardiovascular risk factors in MetS remain elusive [5].
mTOR (the mammalian target of rapamycin) is a
serine/tyrosine kinase. It is an important molecule of
insulin signaling (IS) present in all cells. It lies at the
center of the metabolic pathway and often operates in
parallel to the cAMP pathway [6]
Indeed, IS is a very complex phenomenon which is
influenced not only by the cellular metabolic status but
also interacts with circulating molecules such as hor-
mones (including insulin), nutrients and inflammatory
molecules. mTOR and mTOR homologues are activated
by both specific cytosolic signals which monitor cellular
metabolic status and by extracellular circulating mole-
cules. Accordingly, mTOR influences the energy meta-
bolism, protein synthesis, cell cycles and reparative
processes including anti-apoptotic effects which are
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lates the expression of adhesion molecules and pro-sur-
vival signals in both circulating and endothelial cells
influencing blood circulation and clotting [7,8]. How-
ever, very little data are available on IS of circulating
cells of MetS patients although clinical data show that
inhibited mTOR, with specific inhibitors such as Seroli-
mus or Everolimus after kidney transplantation, signifi-
cantly increase the presence of de novo thrombotic
micro-angiopathy with artery lesion characterized by
intimal cell proliferation, necrosis and narrowed lumen.
Complete withdrawal of mTOR inhibitors leads to
improvement in many cases.
The increased incidence of vascular thrombosis when
mTOR inhibitors are used and the improvement of
micro-angiopathy when these drugs are withdrawn sug-
gest the important role of mTOR in regulating vascular
functions [8,9]
Recently, the effects of leptin on certain IS elements
have been studied in human peripheral mononuclear
cells in patients with MetS, given that the molecular
mechanisms of IS are similar in all human tissue includ-
ing lymphocytes [10]. In this study, the authors showed
that leptin increases serine-138 phosphorylation of insu-
lin receptor substrates-1 (IRS-1). Therefore, IS of insulin
seems to be impaired at least at the IRS-1 level in MetS.
However, the authors did not evaluate the downstream
molecules involved in the intracellular insulin-mediated
signaling including a fundamental molecule such as
mTOR. This is particularly important because blood
samples are easily collected, the procedure is repeatable
and does not have the limitations of invasive approaches
such as muscular biopsies.
Our aim was therefore to investigate the expression of
relevant proteins involved in IS pathway such as mTOR.
Since mTOR regulates blood/endothelial cells survival,
vascular structure and function, and blood coagulation.,
it might be postulated its use as a risk biomarkers of
thrombosis in MetS patients. In this study we applied,
for the first time, a relatively simple and non-invasive
method to evaluate IS in blood lymphocytes of patients
with MetS.
Patients and Methods
Participants
Forty patients with MetS were recruited from subjects
admitted to outpatient clinics. They underwent a com-
prehensive assessment of cardiovascular risk to establish
the prevalence of risk factors. Patients with a previous
diagnosis of diabetes mellitus or who were taking regu-
larly lipid-lowering agents were excluded from the study.
The MetS and metabolic risks were defined according
to the US National Cholesterol Education Program
Adult Treatment Panel III guidelines [11] and modified
as recommended in the latest American Heart Associa-
tion/National Heart, Lung, and Blood Institute Scientific
Statement [12] by adopting a lower cut-off for fasting
glucose (≥5.6 mmol/L). The MetS was defined as having
>3 of the following metabolic risk factors: 1) central
obesity (waist circumference ≥88 cm in women and
≥102 cm in men), 2) hypertriglyceridemia (fasting trigly-
cerides ≥1.7 mmol/L), 3) low HDL cholesterol (fasting
HDL <1.3 mmol/L in women and <1.03 mmol/L in
men), 4) glucose intolerance (fasting glucose ≥5.6
mmol/L), and 5) hypertension (sitting blood pressure
≥130/85 mm Hg obtained as a mean of 2 readings taken
after resting for at least 10 minutes. Hypertensive
patients were previously untreated. A group of 20 age
and sex matched healthy patients were used as controls.
Table 1 shows the baseline characteristics of the sub-
jects. The study protocol was approved by the Ethics
committee of our institution (University of Brescia Med-
ical School), and informed consent was obtained from
each participant, in accordance with institutional
guidelines.
Clinical and Biochemical Assessments
The subjects were examined after an overnight fast of at
least 10 hours. Anthropometric measurements were
made (height, weight, body mass index [BMI], waist cir-
cumference, and blood pressure) and biochemical vari-
ables were evaluated (fasting and 2-hour post-oral
glucose tolerance test glucose, insulin, total cholesterol,
triglycerides, and low-density lipoprotein - LDL and
high-density lipoprotein - HDL cholesterol), as pre-
viously reported [13].
Insulin resistance was estimated with the homeostasis
model assessment index (HOMA), calculated as fasting
glucose (in mmol/L) times fasting insulin (in mIU/L)
divided by 22.5. Erythrosedimentation speed was mea-
sured using standard methods.
Isolation of human peripheral mononuclear cell
Human peripheral mononuclear cells (PMNGCs) were
obtained by Ficoll-Paque density gradient centrifugation
as described [10].
Western Blots
Antibodies against mTOR was obtained from Sigma-
Aldrich (Milano, Italy). Anti-p-p70S6K1, p-4E-BP1 and
p-serine-636/639-IRS-1 were obtained from Cell Signal-
ing Technology (Danvers, MA, USA). Anti-IRS-1 was
obtained from Upstate (Charlottesville, VA, USA) and
anti-Insulin Receptor alpha was from Santa Cruz Bio-
technology (Heidelberg, Germany)
Total proteins were extracted from lymphomonocyte
in lysis buffer (50 mM Tris.Cl pH 7.8, 1% Triton X100,
0.1% SDS, 250 mM NaCl, 5 mM EDTA, 100 mM NaF,
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Page 2 of 82 mM NaPPi, 2 mM Na3VO4, 1 mM PMSF). The crude
lysate was centrifuged at 16000 g for 15 minutes, the
supernatant was recovered and assayed for protein con-
centration by the Bradford Assay. Protein extracts were
run on a 7.5% SDS-PAGE for IRS-1, p-serine 636/639-
IRS-1, Insulin Receptor alpha and mTOR or 15%
SDS-PAGE for p70S6K1, p-4E-BP1, p-p70S6K1 and
transferred onto a PVDF membrane (Millipore, Milano,
Italy). The membranes were stained with Ponceau Red
(Sigma-Aldrich, Milano, Italy) and were blocked at RT
for 2 hours with 10% non-fat dry-milk in TBST contain-
ing 0.1% Tween20. After this, the blots were washed
briefly and incubated with primary antibodies directed
either against p70S6K1 (1:500 for 2 hours at RT), IRS-1
(1:1500 O/N at 4°C), p-serine-636/639-IRS-1 (1:1500 O/
N at 4°C), Insulin Receptor alpha (1:300 for 2 hours at
RT), p-4E-BP1 (1:1500 O/N at 4°C), p-p70S6K1 (1:1000
O/N at 4°C), mTOR (1:3000 for 2 hours at RT) diluted
with 5% non-fat milk or 5% BSA (only for the phos-
phor-specific antibodies) in TBST 0.1% Tween20.
The membranes were then washed 3 times for 10
minutes with TBST. Then, they were incubated for 1
hour at room temperature (RT), with anti-rabbit or
anti-mouse (depending on the primary antibody) HRP-
conjugated secondary antibody (Bio-Rad Laboratories,
Milano, Italy) diluted 1/2000 in TBST containing 5%
non-fat milk. The membranes were washed 3 times for
10 minutes, incubated in SuperSignal West Pico (Pierce
Biotechnology, Rockford, IL, USA) chem-luminescent
substrate and exposed to autoradiography films (Fuji
Photo Film Co., Dusseldorf, Germany). The optical den-
sities of blot bands were finally determined using a com-
puter-assisted densitometer (Rasband, W.S., ImageJ,
U. S. National Institutes of Health, Bethesda, Maryland,
USA, http://rsb.info.nih.gov/ij/, 1997-2006).
Statistical approach
Results are expressed as means ± SEM. The statistical
analysis used one-way analysis of variance analysis. P-
values less than 0.05 were considered significant. As it
was a hypothesis-generating study no corrections for
multiple comparisons were made. All variable were nor-
mally distributed.
Results
The clinical characteristics of our population are sum-
marized in Table 1. We selected subjects with many
signs of MetS to identify intracellular molecular impair-
ment responsible for their pathological conditions.
Indeed, our MetS patients had higher blood pressure
values, BMI, fasting glucose, triglycerides and total or
LDL cholesterol levels as well as a greater prevalence of
hypertension compared with controls. In addition, the
HOMA index and the glucose levels after OGTT were
higher in patients with MetS compared with controls
suggesting that, as expected, insulin resistance was pre-
sent in our subjects.
To avoid possible interference, of IS by other diseases,
we excluded patients with renal or other significant pro-
blems. Indeed, serum creatinine and erythrosedimenta-
tion speed (data not shown) were normal in both
groups.
We found that IS signaling was significantly impaired
in our patients with MetS, as confirmed by significantly
reduced molecular concentrations serine/tyrosine-kinase
mTOR (p < 0.05 vs control) and its downstream
Table 1 Baseline characteristics of subjects according to the presence (MetS) or absence (controls) of metabolic
syndrome.
MetS (n = 40) Controls (n = 20) P
Sex (M/F) 32/8 14/6 NS
Age (years) 60 ± 3 58 ± 2 NS
BMI (Kg/m
2) 30.1 ± 1.2 23.6 ± 0.8 P < 0.01
Blood pressure (mm Hg) 152/89 ± 2/1 129/79 ± 3/2 P < 0.01
Waist circumference 108 ± 5 82 ± 4 P < 0.01
Fasting glucose (mg/dl) 116 ± 7 87 ± 3 P < 0.01
OGTT (serum glucose after 120 min) (mg/dl) 187 ± 8 98 ± 4 P < 0.01
Serum cholesterol (mg/dl) 244 ± 5 186 ± 3 P < 0.01
Serum triglycerides (mg/dl) 207 ± 33 85 ± 20 P < 0.01
LDL cholesterol (mg/dl) 112 ± 7 100 ± 6 NS
HDL cholesterol (mg/dl) 47 ± 5 50 ± 3 NS
Serum creatinine 1.1 ± 0.1 0.9 ± 0.1 NS
Fasting insulin (μIU/mL) 12.0 ± 0.9 3.71 ± 0.4 P < 0.001
HOMA index 3.45 ± 2 0.8 ± 0.6 P < 0.01
OGTT: oral glucose tolerance test
HOMA index = Fasting insulin (μIU/mL)* fasting plasma glucose (FPG) (mmol/L)/22.5.
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and p < 0.05 vs controls). (Figure 1, 2 and 3
respectively).
In addition, we analyzed the molecules upstream of
mTOR involved in cellular insulin signaling as illu-
strated in figure 4, 5 and 6. We therefore evaluated
intracellular concentrations of insulin receptors, total
IRS-1 and the serine-636/639 phosphorylated form of
IRS-1 (p-serine-636/639-IRS-1). Figure 4 shows the
insulin receptor expression, Figure 5 total IRS-1 and
Figure 6 inactive form of IRS-1 in humans (serine-636/
639-phosphorylated-IRS-1). We evaluated both total
IRS-1 and its inactive form for a better idea of the insu-
lin molecular cascade. We found that there were signifi-
cantly fewer insulin receptors in patients with MetS (p <
0.03 vs. controls) suggesting a possible down-regulation
process, as a consequence of the high blood insulin
concentrations.
Discussion
Our results strongly suggest that: a) it is possible to eval-
uate IS in blood cells such as lymphocytes, using a rela-
tively simple and repeatable procedure, b) mTOR, which
regulates replacement of damaged blood and endothelial
cells with consequent maintenance of vasculature integ-
rity and potential regulation of thrombotic phenomena
and other molecules involved in the intracellular IS are
significantly altered in patients with MetS. Consequently,
mTOR cellular expression can be used to evaluate the
disease status and the risk of vascular thrombosis.
Intracellular Insulin Signaling
Reduced mTOR has many important consequences for
cell metabolism and life span. Indeed, mTOR is stimu-
lated by insulin signaling, nutrients, catabolic hormones,
cytokines and growth factors [7]. It activates not only
the protein synthesis through the phosphorylation of the
enzyme p70S6K1 but also regulates important enzymes
for cell life. Inhibition of mTOR reduces translocation
mTOR
0
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Figure 1 Intracellular concentrations of mTOR evaluated by
Western blot (absorbance units). *p < 0.05 vs. Controls.
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*
Figure 2 Intracellular concentrations of phosphorylated-
p70S6K1 (p-p70S6K1), evaluated by Western blot (absorbance
units). *p < 0.05 vs. Controls.
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Figure 4 Intracellular concentrations of Insulin Receptor,
evaluated by Western blot (absorbance units). *p < 0.05 vs.
Controls.
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Figure 3 Intracellular concentrations of phosphorylated-4E-BP1
(p-4E-BP1), evaluated by Western blot (absorbance units).
*p < 0.05 vs. Controls.
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mal mRNA and tRNA transcription. In addition, the use
of specific mTOR blockers stop cell cycle progression in
the early G1 phase of the cell cycle, driving cells into
G0 state promoting apoptotic processes [14,15]. More-
over, mTOR not only avoids blood/endothelial cellular
apoptosis but also probably repairs and replaces
damaged endothelial cells stimulating endothelial pro-
genitor cells with consequent maintenance of vascular
functions including blood coagulation [8].
The role of mTOR in regulating blood coagulation has
been recently clinically demonstrated. Indeed, cases of
important de novo thrombotic micro-angiopathy have
been reported in renal recipients treated with the mTOR
inhibitor Sirolimus and Everolimus [8,9]. Treatment of
micro-angiopathy is based on removal of these drugs.
This would indicate that mTOR inhibition is crucial to
decrease thrombotic events. Consequently, the significant
reduction of mTOR found in MetS patients suggests that
mTOR might be, in part, responsible for increased cardi-
ovascular thrombotic diseases seen in MetS.
In addition, we know that mTOR and other molecules
linked with this kinase, are influenced by circulating
inflammatory cytokines and the nervous system. Indeed,
cytokines such as TNF alpha - which are high in MetS-
patient blood cause serine phosphorylation of IRS-1 and
inhibit its tyrosine phosphorylation with consequent
impairment of mTOR function [16].
Interestingly, Morisco et al. also recently demon-
strated the presence of a cross-talk between b-adrener-
gic stimulation and IS by AKT, suggesting that there is
an inter-relationship between the activation of the sym-
pathetic nervous system and IS including AKT which
influences mTOR function [17]. The role of mTOR and
cross-talk with inflammatory and sympathetic systems
and insulin signaling are very new and interesting obser-
vations and deserve further study to understand the
molecular pathophysiology responsible for the increased
cardiovascular disease associated with MetS. Moreover,
we have recently shown that maintenance of cellular
mTOR function by anti-hypertensive drugs improves
insulin signaling increasing GLUT 4 expression and pre-
vents micro-vascular rarefaction in spontaneously hyper-
tensive rats with insulin resistance. This effect was
independent of the reduction of blood pressure but was
mTOR-related. [18].
We also found impairment of intracellular insulin sig-
naling in patients with MetS. Indeed, insulin signaling is
a complex phenomenon where mTOR plays a funda-
mental role. [5,7]. In detail, insulin binding to its specific
receptor leads to the autophosphorylation of the trans-
membrane b receptor sub-units and tyrosine phosphory-
lation of IRS-1 after their recruitment to the cell mem-
brane. When IRS-1 is activated, it stimulates GLUT 4,
with consequent regulation of glucose and lipid intracel-
lular metabolism. In addition, activated IRS-1 modulates
the phosphoinositide 3-kinase (PI3K) that in turn indir-
ectly stimulates the activity of mTOR [19]. As discussed
before, mTOR is a central regulator of cellular responses
to hormones, growth factors and nutrients [7,20]. Cur-
rent understanding of insulin signaling regulation con-
siders IRS-1 to be a key protein in this cascade and
mTOR activation.
The main cellular molecular mechanism of insulin
desensitization, with consequent insulin resistance
presents in MetS-patients, involves increased serine
phosphorylation and decreased tyrosine phosphoryla-
tion of IRS-1. This is true in type 2 diabetic patients
as well as in experimental models of insulin resistance.
Phosphorylation of the tyrosine residues 608 on IRS-1
after insulin stimulation is necessary for propagation
of the signal with consequent active-mTOR
expression.
5000
Total IRS-1
0
1000
2000
3000
4000
5000
Adsorb. 
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MetS
Figure 5 Intracellular concentrations of total IRS-1, evaluated
by Western blot (absorbance units).
p-IRS-1
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*
Figure 6 Intracellular concentrations of serine-636/639-
phosphorylated (inactive) form of IRS-1, evaluated by Western
blot (absorbance units). *p < 0.05 vs. Controls.
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leads to reduced insulin signaling [21,22]. It has therefore
been proposed that changes in the equilibrium between
serine or tyrosine phosphorylation lead to pathological
conditions of insulin resistance and diabetes.
IRS-1 function is also negatively regulated by other
circulating molecules found in the MetS such as cata-
bolic hormones and inflammatory molecules [17].
Indeed, recent data has shown that the cytokine leptin
promotes phosphorylation of serine 318 in IRS-1 in
both skeletal muscle and in lymphocytes of obese and
diabetic hyperleptinemic patients [10]. This would sug-
gest: 1) that cytokines impair IRS-1 activity, blocking
anabolic insulin signaling cascade with less activated
m T O Ra n d2 )t h a tt h em o l e c u lar mechanism of leptin-
mediated impairment of insulin signaling is similar in
both skeletal muscle and lymphocytes.
Surprisingly, in our study p-serine-636/639-IRS-1 was
significantly less in patients with MetS while there was a
slight increased total IRS-1, although this was not statis-
tical significant. We can explain these findings by con-
sidering that serine phosphorylated IRS-1 is rapidly
eliminated in the cell cytoplasm like many other acti-
vated or deactivated molecules involved in intracellular
signaling. Therefore, we probably observed the amount
of p-serine-636/639-IRS-1 in the cell after its degrada-
tion. Indirect confirmation was the slightly increased
total IRS-1, suggesting the cell’s attempt to maintain
adequate total concentrations of IRS-1 which could be
activated or inactivated in response to specific stimuli.
All these intracellular molecular data explain the phe-
nomenon of insulin resistance present in patients with
MetS.
Patients with MetS, in particular those with overt dia-
betes mellitus, are disproportionately affected by cardio-
vascular disease, compared with those without diabetes,
due to a particularly pronounced atherosclerosis pro-
gression. Evidences suggest that insulin-resistance, dia-
betes and coronary heart disease share in common a
deregulation of ubiquitin-proteasome system, a major
pathway for nonlysosomal intracellular protein degrada-
tion in eucaryotic cells [23]. This might represent a
common persistent pathogenic factor mediating the
initial stage of the atherosclerosis as well as the progres-
sion to complicated plaque in diabetic patients [23].
In obesity and in diabetes mellitus, an increase in
plasma free fatty acids, even still within the physiological
range, might induces markers of endothelial activation,
vascular inflammation and thrombosis [24]. Even transi-
ent and modest increases in plasma free fatty acids, also
seen in healthy subjects may initiate early vascular
abnormalities that promote atherosclerosis and cardio-
vascular disease [24]. Finally, also changes in the
immune system might play a role in cardiovascular
pathology. Biological processes altered in T cell aging
are not only those typically associated with immune
cells (T cell receptor signalling, cytokine-cytokine recep-
tor interactions, etc.) but also some not specific of
immune cells, such as peroxisome proliferator-activated
receptors and mTOR signalling, as well as glucose and
glutathione metabolism, suggesting that T cell aging
may be representative of a more generalized aging phe-
nomenon [25], with features characteristic also of the
MetS.
Surprisingly enough, our patients with or without
MetS do not differ significantly in the levels of HDL
cholesterol, although patients with MetS tended to have
lower values. We have no good explanation for this
observation, apart from the relatively modest number of
patients and subjects evaluated.
The clinical perspective
MetS has many different clinical signs which include
obesity, hypertension, diabetes and alteration of lipid
metabolism [26]. Furthermore, recent research has
shown that circulating molec u l e ss u c ha ss t r e s sh o r -
mones and inflammatory cytokines increase in patients
with MetS and they can influence and/or worsen IS
including the central role of mTOR.
However, little is known about the intracellular mole-
cular mechanisms present in MetS. We have demon-
s t r a t e dt h a tI Si si m p a i r e di np a t i e n t sw i t hM e t S .
Consequently, the observed molecular alterations can be
used as biomarkers of this disease and its evolution.
We not only analyzed mTOR but also its downstream
effectors p70S6K and 4EPB1 which stimulate anabolic
pathway and other fundamental biochemical pathways
such as the production of adhesion molecules, replace
damaged cells and cell survival (including blood and
endothelial cells with consequent regulation of blood
coagulation). We also investigated the molecules which
regulate important intracellular metabolic pathway such
as cellular insulin stimulated molecules.
For mTOR evaluations we have developed a method
that allows the study of IS in human peripheral mono-
nuclear cells. We believe that our method has some
relevant advantages; these are namely; 1) it is relatively
easy to perform and may be repeated several time in the
same subject, allowing the evaluation of time the time
course of changes or the effect of treatment, 2) it avoids
the pain or discomfort related to muscle biopsies, 3) it
allows us to identify and quantify intracellular molecular
damage and/or to study molecules which could link
MetS, sympathetic activation and cell energy regulation.
In addition, as it is repeatable, this method could be
useful to assess the effects of interventions with specific
therapeutic strategies such as drugs, weight reduction
and/or physical training. Further investigation is needed
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cular alterations and cardiovascular disease in a large
scale study.
Conclusion
In conclusion, using a relative simple and repeatable
method, we analyzed intracellular molecules involved in
IS and demonstrated impairments of important mole-
cules as mTOR. mTOR modification is an important
biomarker of cardiovascular risk factors not only
because it compromises cell energetic metabolism and
metabolic fluxes but also because mTOR regulates fun-
damental functions of blood and endothelial cell which,
in turn, modulate blood/vascular interaction and integ-
rity stimulating or avoiding vascular thrombosis.
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